Mayo Clinic | Strategic Alliance Partners

Alan H. Bryce, MD, discusses the recent regulatory approval of rucaparib in metastatic castration-resistant prostate cancer and explains how the approval has underscored the importance of genetic testing in the field.

Alan H. Bryce, MD, discusses the recent regulatory approval of rucaparib in metastatic castration-resistant prostate cancer and explains how the approval has underscored the importance of genetic testing in the field.

Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Carlos E. Vargas, MD, discusses research with proton therapy in prostate cancer.

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses moving metastatic treatment strategies to the adjuvant setting in colorectal cancer (CRC).

Tanios S. Bekaii-Saab, MD, FACP, discusses the need for umbrella trials in biliary tract cancer.

Shaji Kumar, MD, discusses the role of stem cell transplant in multiple myeloma, different techniques for stem cell mobilization, and remaining challenges faced with this modality.

Anastasios (Tassos) Dimou, MD, discusses the progress made in the treatment of patients with ALK-positive lung cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the impact of the novel coronavirus 2019 on telemedicine.

OncLive interviewed experts at the State of the Science Summits™ in March 2020 on the impact of the COVID-19 pandemic on cancer care and shared what advice they have been giving their patients.

Tanios S. Bekaii-Saab, MD, FACP, discusses the shift toward telemedicine, the impact of protective strategies on the trajectory of COVID-19, and the potential aftereffects of the virus.

Stephen A. Boorjian, MD, professor of urology, Mayo Clinic, discusses research with intravesical nadofaragene firadenovec in patients with nonmuscle invasive bladder cancer (NMIBC).

Experts from Mayo Clinic, Ironwood Cancer and Research Centers, and Banner MD Anderson Cancer Center Clinic discuss the impact of the COVID-19 pandemic on cancer care and shared what advice they have been giving their patients.

Terence T. Sio, MD, MS, discusses the utility of proton therapy in lung cancer.

Anastasios Dimou, MD, discusses available and emerging treatment options and approaches for patients with oncogenic-driven lung cancer.

Panayiotis S. Savvides, MD, discusses the results of the KEYNOTE-407 and IMpower131 trials and how the data have impacted the treatment of patients with stage IV squamous non–small cell lung cancer.

Jonathan D'Cunha, MD, PhD, FACS, discusses surgical options for high-risk patients with lung cancer.

Carrie L. Langstraat, MD, discusses the role of sentinel lymph node biopsy in endometrial cancer.

Terence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.

Anastasios (Tassos) Dimou, MD, discusses the limitations of tumor mutational burden as a biomarker in lung cancer.

Researchers at the Mayo Clinic maintain that all women aged 65 or under with a breast cancer diagnosis should receive germline genetic testing to identify harmful mutations that increase their risk of developing secondary cancers.

Carlos E. Vargas, MD, examines the use of stereotactic body radiation therapy (SBRT) in oligometastatic prostate cancer.

Alan H. Bryce, MD, discusses ongoing research regarding CDK12 alterations in prostate cancer.

Alan H. Bryce, MD, assistant professor of medicine and medical director of the Genomic Oncology Clinic, Mayo Clinic, discusses ongoing research in prostate cancer.

We traveled to Phoenix, Arizona, for a State of the Science Summit™ on Genitourinary Cancers, which featured insights from the Mayo Clinic and Benner MD Anderson Cancer Center faculty.

Pashtoon M. Kasi, MD, discusses the recycling of therapies in patients with colorectal cancer (CRC).

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the use of next-generation radiopharmaceuticals in prostate cancer.

Matthew P. Goetz, MD, Mayo Clinic, discusses the use of circulating tumor DNA in the phase III MONARCH-3 trial in hormone receptor–positive, HER2-negative breast cancer.